The PRIME and PRIME2 studies both showed that the IL-4 and IL-13 inhibitor significantly improved disease signs and symptoms compared to placebo, including reduction in itch and skin lesions.
Brandon Joseph, 20, opens up to PEOPLE seven years after his first interview. He talks about overcoming daily challenges and becoming more independent while living with epidermolysis bullosa, a rare ...
German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...
Jason McCarthy’s rating is based on a combination of factors related to Azitra Inc’s recent progress and future potential in developing treatments for rare skin diseases. The company’s ...
I do as much as I can by myself, but I'm always willing to ask for help.” Related: Model, 24, with Rare Skin Disease Bares Scars to Raise Awareness: 'I Choose to Show the Body I Was Given' Andre ...